Skip to main content

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Closes on Acquisition of Uncle Bud’s in All-Stock Transaction

Pressure BioSciences (OTCQB: PBIO), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics and more, has closed on the acquisition of natural health and wellness leader Uncle Bud’s (“UB”). The acquisition was an all-stock transaction. According to the announcement, the acquisition includes UB’s 70-plus products, 865,000-member online community, existing online sales channels online and leading large retailers, celebrity spokesperson relationships, and invaluable experience building successful consumer products businesses. The acquisition will allow PBIO to leverage and integrate its revolutionary UltraShear(TM) technology platform for further improved nanoemulsified products. According to company officials, the acquisition will position PBIO “with a fast forward integration capability that will allow us to selectively set the timing and drive the pace of revolutionary change across multiple major markets.

This rapid growth engine provides a central platform to leverage new growth capital, restructure and strengthen our balance sheet, and complete our drive to uplist to a national stock exchange in 2024.” A leader in the hemp and CBD space, Uncle Bud’s products are made in America, are GMO and cruelty free, and are Leaping Bunny certified. “This transaction combines the existing momentum and ready market execution power of Uncle Bud’s with the pivotal scientific and product breakthrough of the UltraShear nanoemulsions processing platform for record-setting product performance and long-term stability,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In 2024 alone, we are forecasting a five-fold leap forward in PBIO revenues to over $10 million, but this is only a steppingstone towards revolutionary impact and sales growth that we expect to achieve across the nutraceuticals, cosmeceuticals, skincare, food/beverage, agrochemical and other major markets in the following years.”

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. PBIO’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counterbioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing PBIO to enter the biopharma contract services and GMP manufacturing equipment sector. PBIO has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office

InvestorWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.